BYSI:NSD-BeyondSpring Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 15.43

Change

+0.08 (+0.52)%

Market Cap

USD 0.60B

Volume

1.25M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

Company Website : http://www.beyondspringpharma.com

Address : 28 Liberty Street, New York, NY, United States, 10005

Employees : 91

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.86

52 Week High : 33.00

Short Ratio : 0.27

52 Week Low : 8.90

Shorted Shares : 2,232,135

200 Day Moving Average : 13.93

Shorted Shares Previous Month : 1,796,487

50 Day Moving Average : 23.57

Shares Held By Insiders : 68.70%

Short Percentage : 6.00%

Shares Held by Institutions : 20.24%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-24.46 (-5.38%)

 USD183.50B 53.71 41.56
BNTX BioNTech SE

-19.51 (-5.53%)

 USD82.28B 18.73 15.10
REGN Regeneron Pharmaceuticals Inc

-7.61 (-1.18%)

 USD69.15B 11.67 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.48 (-0.80%)

 USD48.02B 24.40 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-5.90 (-1.53%)

 USD37.14B N/A N/A
SGEN Seagen Inc

-4.88 (-2.94%)

 USD30.24B 51.86 39.11
GMAB Genmab A/S

-1.45 (-3.23%)

 USD28.89B 73.39 8.17
RPRX Royalty Pharma plc

-0.03 (-0.08%)

 USD22.54B 30.06 12.50
ALNY Alnylam Pharmaceuticals Inc

+0.45 (+0.24%)

 USD22.22B N/A N/A

ETFs Containing BYSI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 26.48% 76% C 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.48% 76% C 73% C
Trailing 12 Months  
Capital Gain 17.43% 60% D- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.43% 60% D- 37% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -15.85% 15% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.85% 15% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 29.41% 87% B+ 62% D-
Risk Adjusted Return -53.89% 11% F 4% F
Market Capitalization 0.60B 63% D 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 16.20 8% F 8% F
Price / Cash Flow Ratio -13.73 66% D 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -158.58% 14% F 15% F
Return on Invested Capital -105.79% 18% F 7% F
Return on Assets -69.01% 6% F 2% F
Debt to Equity Ratio 2.50% 72% C- 83% B
Technical Ratios  
Short Ratio 0.27 94% A 91% A-
Short Percent 10.87% 20% F 15% F
Beta 0.86 73% C 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector